Perilous Reversal Stock: Supernus Pharmaceuticals (SUPN)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Supernus Pharmaceuticals ( SUPN) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Supernus Pharmaceuticals as such a stock due to the following factors:

  • SUPN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $42.2 million.
  • SUPN has traded 220,039 shares today.
  • SUPN is down 3% today.
  • SUPN was up 6.7% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SUPN with the Ticky from Trade-Ideas. See the FREE profile for SUPN NOW at Trade-Ideas

More details on SUPN:

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. SUPN has a PE ratio of 22. Currently there are 5 analysts that rate Supernus Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Supernus Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Supernus has a market cap of $764.7 million and is part of the health care sector and drugs industry. The stock has a beta of 0.81 and a short float of 6.4% with 0.86 days to cover. Shares are up 92.9% year-to-date as of the close of trading on Thursday.

If you liked this article you might like

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Anika Up on Strong Analyst Ratings